“COVAXIN” gets approval from DGCI : India’s first probable vaccine for COVID-19


NEW DELHI | JUNE 30, 2020 :

Directorate General of Commercial Intelligence and Statistics (DGCI) has officially approved clinical trials of COVAXIN, to be conducted on humans. This will be the first potential COVID-19 Vaccine developed in the country.

According to AIR report, the Central Drug Standard Control Organisation, the National regulatory body for Indian pharmaceuticals and medical devices, has approved of Bharat Biotech India to conduct human clinical trials for Corona Vaccine called 'Covaxin'.

It may be mentioned that Covaxin is the first vaccine in the nation to have been authorized for a human trial. It is a collaborative development with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), Pune.

Managing Director of Bharat Biotech Dr. Krishna Ella informed that these trials are likely to commence treatments in July.

While speaking on the effectiveness of the medicine, Dr. Krishna affirmed that the permission was given after the company submitted results from pre-clinical studies of the vaccine that demonstrated its safety and immune response.